Topiramate use and the risk of glaucoma development: A population-based follow-up study

Jau Der Ho, Joseph J. Keller, Ching Yao Tsai, Shiow Wen Liou, Chih Ju Chang, Herng Ching Lin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To investigate the risk of glaucoma development after being prescribed topiramate. Design: A retrospective, population-based cohort study using an administrative database. Methods: The study group comprised 1956 patients who received their first prescription of topiramate between 2001 and 2007. The comparison cohort consisted of 15 648 randomly matched patients who never took topiramate. Each sampled patient was traced for a 1-year period from his or her index date to identify patients who subsequently received a diagnosis of glaucoma. Results: Glaucoma was diagnosed in 0.36%, 0.05%, and 0.66% of the study cohort during the first month, second to third month, and fourth to twelfth month following the index date, respectively. For the comparison cohort, glaucoma was diagnosed in 0.04%, 0.11%, and 0.46% of subjects during the first month, second to third month, and fourth to twelfth month following the index date, respectively. After adjusting for potential confounding factors, patients prescribed topiramate were found to have a 7.41-fold (95% confidence interval [CI] = 2.45-22.46) greater risk of subsequently being diagnosed with glaucoma than the comparison cohort during the first month after the index date. However, this association became statistically nonsignificant during the second-to-third-month and fourth-to-twelfth-month periods following the index date between the 2 cohorts (adjusted hazard ratio, 0.56, 95% CI = 0.07-4.29; and 1.35, 95% CI = 0.74-2.47, respectively). Conclusions: Topiramate use in Taiwan was associated with a significantly increased risk of being diagnosed with glaucoma within the first month after receiving a prescription for the drug.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume155
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Glaucoma
Population
Confidence Intervals
Cohort Studies
Prescription Drugs
Taiwan
Prescriptions
topiramate
Databases

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Topiramate use and the risk of glaucoma development : A population-based follow-up study. / Ho, Jau Der; Keller, Joseph J.; Tsai, Ching Yao; Liou, Shiow Wen; Chang, Chih Ju; Lin, Herng Ching.

In: American Journal of Ophthalmology, Vol. 155, No. 2, 02.2013.

Research output: Contribution to journalArticle

Ho, Jau Der ; Keller, Joseph J. ; Tsai, Ching Yao ; Liou, Shiow Wen ; Chang, Chih Ju ; Lin, Herng Ching. / Topiramate use and the risk of glaucoma development : A population-based follow-up study. In: American Journal of Ophthalmology. 2013 ; Vol. 155, No. 2.
@article{bdc3c7c028114579870f2f6c044df497,
title = "Topiramate use and the risk of glaucoma development: A population-based follow-up study",
abstract = "Purpose: To investigate the risk of glaucoma development after being prescribed topiramate. Design: A retrospective, population-based cohort study using an administrative database. Methods: The study group comprised 1956 patients who received their first prescription of topiramate between 2001 and 2007. The comparison cohort consisted of 15 648 randomly matched patients who never took topiramate. Each sampled patient was traced for a 1-year period from his or her index date to identify patients who subsequently received a diagnosis of glaucoma. Results: Glaucoma was diagnosed in 0.36{\%}, 0.05{\%}, and 0.66{\%} of the study cohort during the first month, second to third month, and fourth to twelfth month following the index date, respectively. For the comparison cohort, glaucoma was diagnosed in 0.04{\%}, 0.11{\%}, and 0.46{\%} of subjects during the first month, second to third month, and fourth to twelfth month following the index date, respectively. After adjusting for potential confounding factors, patients prescribed topiramate were found to have a 7.41-fold (95{\%} confidence interval [CI] = 2.45-22.46) greater risk of subsequently being diagnosed with glaucoma than the comparison cohort during the first month after the index date. However, this association became statistically nonsignificant during the second-to-third-month and fourth-to-twelfth-month periods following the index date between the 2 cohorts (adjusted hazard ratio, 0.56, 95{\%} CI = 0.07-4.29; and 1.35, 95{\%} CI = 0.74-2.47, respectively). Conclusions: Topiramate use in Taiwan was associated with a significantly increased risk of being diagnosed with glaucoma within the first month after receiving a prescription for the drug.",
author = "Ho, {Jau Der} and Keller, {Joseph J.} and Tsai, {Ching Yao} and Liou, {Shiow Wen} and Chang, {Chih Ju} and Lin, {Herng Ching}",
year = "2013",
month = "2",
doi = "10.1016/j.ajo.2012.07.016",
language = "English",
volume = "155",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Topiramate use and the risk of glaucoma development

T2 - A population-based follow-up study

AU - Ho, Jau Der

AU - Keller, Joseph J.

AU - Tsai, Ching Yao

AU - Liou, Shiow Wen

AU - Chang, Chih Ju

AU - Lin, Herng Ching

PY - 2013/2

Y1 - 2013/2

N2 - Purpose: To investigate the risk of glaucoma development after being prescribed topiramate. Design: A retrospective, population-based cohort study using an administrative database. Methods: The study group comprised 1956 patients who received their first prescription of topiramate between 2001 and 2007. The comparison cohort consisted of 15 648 randomly matched patients who never took topiramate. Each sampled patient was traced for a 1-year period from his or her index date to identify patients who subsequently received a diagnosis of glaucoma. Results: Glaucoma was diagnosed in 0.36%, 0.05%, and 0.66% of the study cohort during the first month, second to third month, and fourth to twelfth month following the index date, respectively. For the comparison cohort, glaucoma was diagnosed in 0.04%, 0.11%, and 0.46% of subjects during the first month, second to third month, and fourth to twelfth month following the index date, respectively. After adjusting for potential confounding factors, patients prescribed topiramate were found to have a 7.41-fold (95% confidence interval [CI] = 2.45-22.46) greater risk of subsequently being diagnosed with glaucoma than the comparison cohort during the first month after the index date. However, this association became statistically nonsignificant during the second-to-third-month and fourth-to-twelfth-month periods following the index date between the 2 cohorts (adjusted hazard ratio, 0.56, 95% CI = 0.07-4.29; and 1.35, 95% CI = 0.74-2.47, respectively). Conclusions: Topiramate use in Taiwan was associated with a significantly increased risk of being diagnosed with glaucoma within the first month after receiving a prescription for the drug.

AB - Purpose: To investigate the risk of glaucoma development after being prescribed topiramate. Design: A retrospective, population-based cohort study using an administrative database. Methods: The study group comprised 1956 patients who received their first prescription of topiramate between 2001 and 2007. The comparison cohort consisted of 15 648 randomly matched patients who never took topiramate. Each sampled patient was traced for a 1-year period from his or her index date to identify patients who subsequently received a diagnosis of glaucoma. Results: Glaucoma was diagnosed in 0.36%, 0.05%, and 0.66% of the study cohort during the first month, second to third month, and fourth to twelfth month following the index date, respectively. For the comparison cohort, glaucoma was diagnosed in 0.04%, 0.11%, and 0.46% of subjects during the first month, second to third month, and fourth to twelfth month following the index date, respectively. After adjusting for potential confounding factors, patients prescribed topiramate were found to have a 7.41-fold (95% confidence interval [CI] = 2.45-22.46) greater risk of subsequently being diagnosed with glaucoma than the comparison cohort during the first month after the index date. However, this association became statistically nonsignificant during the second-to-third-month and fourth-to-twelfth-month periods following the index date between the 2 cohorts (adjusted hazard ratio, 0.56, 95% CI = 0.07-4.29; and 1.35, 95% CI = 0.74-2.47, respectively). Conclusions: Topiramate use in Taiwan was associated with a significantly increased risk of being diagnosed with glaucoma within the first month after receiving a prescription for the drug.

UR - http://www.scopus.com/inward/record.url?scp=84872299046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872299046&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2012.07.016

DO - 10.1016/j.ajo.2012.07.016

M3 - Article

C2 - 23022160

AN - SCOPUS:84872299046

VL - 155

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 2

ER -